

Andreas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6420766/publications.pdf>

Version: 2024-02-01

106
papers

6,515
citations

94269

37
h-index

66788

78
g-index

120
all docs

120
docs citations

120
times ranked

6847
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	0.6	82
2	Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	2.5	17
3	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
4	Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 664-670.	1.7	30
5	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations – a registry based analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1432-1440.	0.6	7
6	IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. <i>Cancers</i> , 2021, 13, 764.	1.7	14
7	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	3.3	40
8	Reply to S. Fuji. <i>Journal of Clinical Oncology</i> , 2021, 39, 1412-1413.	0.8	2
9	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	1.7	7
10	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	2.5	21
11	The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). <i>Leukemia</i> , 2021, 35, 2917-2923.	3.3	16
12	Value and Diagnostic Accuracy of Ultrasound-Guided Full Core Needle Biopsy in the Diagnosis of Lymphadenopathy: A Retrospective Evaluation of 793 Cases. <i>Journal of Ultrasound in Medicine</i> , 2020, 39, 559-567.	0.8	7
13	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i> Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	0.8	335
14	Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e395-e398.	1.7	0
15	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29
16	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. <i>Leukemia</i> , 2020, 34, 2074-2086.	3.3	50
17	Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). <i>Leukemia</i> , 2020, 34, 2276-2278.	3.3	23
18	Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe disease. <i>Nature Communications</i> , 2020, 11, 1338.	5.8	32

#	ARTICLE	IF	CITATIONS
19	Pathologic Hepatic Contrast-Enhanced Ultrasound Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 1865-1871.	0.7	9
20	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <i>PCM1</i> , <i>JAK2</i> , <i>BCR-ABL1</i> and <i>ETV6-ABL1</i> fusion genes. <i>American Journal of Hematology</i> , 2020, 95, 824-833.	1.0	46
21	Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML. <i>Journal of Hematology and Oncology</i> , 2019, 12, 72.	6.9	12
22	Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2149-2156.	1.2	3
23	Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2056-2061.	0.6	2
24	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
25	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	1.7	18
26	High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels. <i>Blood</i> , 2019, 134, 666-666.	0.6	2
27	Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response. <i>Blood</i> , 2019, 134, 495-495.	0.6	13
28	Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 266-271.	0.2	18
29	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
30	High β -1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. <i>Oncolmmunology</i> , 2018, 7, e1423169.	2.1	10
31	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , 2018, 19, 747-757.	5.1	444
32	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e161-e169.	2.2	67
33	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281.	2.0	16
34	The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 295.	1.0	30
35	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2018, 78, 6223-6234.	0.4	16
36	Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. <i>Blood</i> , 2018, 132, 460-460.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial. <i>Blood</i> , 2018, 132, 661-661.	0.6	87
38	EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1528-1528.	0.6	1
39	Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1461-1461.	0.6	3
40	Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial. <i>Blood</i> , 2018, 132, 210-210.	0.6	1
41	Pathological Hepatic Contrast-Enhanced Ultrasound (CEUS) Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2018, 132, 3359-3359.	0.6	0
42	Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. <i>Leukemia</i> , 2017, 31, 829-836.	3.3	74
43	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	0.8	36
44	Long-term survival of sorafenib-treated FLT3-ITD“positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. <i>European Journal of Cancer</i> , 2017, 86, 233-239.	1.3	59
45	Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). <i>Leukemia</i> , 2017, 31, 2523-2525.	3.3	71
46	Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. <i>Leukemia</i> , 2017, 31, 2398-2406.	3.3	232
47	PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 317-320.	1.3	81
48	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	0.6	20
49	Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. <i>Blood</i> , 2017, 130, 897-897.	0.6	7
50	Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7049-7049.	0.8	0
51	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	0.6	10
52	NFATc1 as a therapeutic target in FLT3-ITD-positive AML. <i>Leukemia</i> , 2015, 29, 1470-1477.	3.3	39
53	Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1331-1335.	3.3	51
54	Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. <i>Leukemia</i> , 2015, 29, 1123-1132.	3.3	248

#	ARTICLE	IF	CITATIONS
55	Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2015, 56, 2690-2698.	0.6	6
56	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia</i> , 2015, 29, 2062-2068.	3.3	455
57	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. <i>Blood</i> , 2015, 126, 42-49.	0.6	171
58	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	5.1	347
59	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. <i>Annals of Hematology</i> , 2015, 94, 2015-2024.	0.8	67
60	Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial. <i>Blood</i> , 2015, 126, 4344-4344.	0.6	16
61	Impact of unbalanced karyotypes at diagnosis on prognosis of CML. <i>Journal of Clinical Oncology</i> , 2015, 33, 7041-7041.	0.8	0
62	Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 9-16.	1.2	9
63	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. <i>Annals of Hematology</i> , 2014, 93, 279-285.	0.8	21
64	Chronische myeloische Leukämie. , 2014, , 1-11.		0
65	Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. <i>Bone Marrow Transplantation</i> , 2013, 48, 403-407.	1.3	45
66	Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial. <i>Blood</i> , 2013, 122, 3315-3315.	0.6	6
67	Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. <i>Blood</i> , 2012, 119, 530-539.	0.6	81
68	Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?. <i>Blood</i> , 2012, 119, 2965-2966.	0.6	7
69	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. <i>Leukemia</i> , 2012, 26, 2353-2359.	3.3	208
70	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1035-1044.	5.1	237
71	BCR-ABL-Induced Transcriptional Repression of the Interferon Regulatory Factor 8 (IRF-8/ICSBP) Leads to Depletion of Plasmacytoid Dendritic Cells (PDC), Which May Contribute to Leukemogenesis in a Murine Model of Chronic Myeloid Leukemia. <i>Blood</i> , 2012, 120, 36-36.	0.6	1
72	Differential diagnosis of pericardial effusion after stem cell transplantation in acute myeloid leukemia. <i>Herz</i> , 2011, 36, 352-354.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2031-2035.	0.6	2
74	IRF8 Regulates Acid Ceramidase Expression to Mediate Apoptosis and Suppresses Myelogenous Leukemia. <i>Cancer Research</i> , 2011, 71, 2882-2891.	0.4	62
75	Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis. <i>Blood</i> , 2011, 118, 1019-1019.	0.6	3
76	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , 2011, 118, 157-157.	0.6	1
77	Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1429-1435.	0.8	153
78	Reply to V. Pitini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e440-e440.	0.8	1
79	Sorafenib Monotherapy Is Effective In Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3314-3314.	0.6	4
80	Compassionate use of sorafenib in FLT3-ITD positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. <i>Blood</i> , 2009, 113, 6567-6571.	0.6	245
81	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009, 114, 5264-5270.	0.6	366
82	Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2060-2060.	0.6	7
83	Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSC CLL3X study). <i>Blood</i> , 2008, 112, 565-565.	0.6	6
84	Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and the Formation of Nuclear Bodies in Myeloid Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 5633-5640.	1.6	40
85	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. <i>Blood</i> , 2007, 109, 2147-2155.	0.6	135
86	Roots of imatinib resistance: A question of self-renewal?. <i>Drug Resistance Updates</i> , 2007, 10, 152-161.	6.5	21
87	Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. <i>Leukemia</i> , 2007, 21, 1267-1275.	3.3	200
88	Diffuse pneumatosis due to central venous catheterization in a patient with acute graft-versus-host disease. <i>Annals of Hematology</i> , 2007, 86, 767-769.	0.8	0
89	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. <i>Endocrine</i> , 2007, 31, 105-113.	1.1	28
90	Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2007, 110, 683-683.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. <i>Thrombosis and Haemostasis</i> , 2006, 95, 708-714.	1.8	27
92	FLT3-ITD, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. <i>Blood</i> , 2006, 107, 2094-2097.	0.6	26
93	Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 437-443.	3.3	59
94	Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors: a novel antiproliferative/antiangiogenic strategy in thyroid cancer. <i>Langenbeck's Archives of Surgery</i> , 2006, 391, 589-596.	0.8	30
95	Adaptive Autocrine Secretion of the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Mediates Imatinib- and Nilotinib-Resistance in BCR/ABL-Positive Progenitors Via JAK-2/STAT-5 Pathway Activation.. <i>Blood</i> , 2006, 108, 2187-2187.	0.6	0
96	Knockdown of the Nuclear Oncogene SKI Inhibits Flt3-ITD Induced Signaling in 32D - Flt3-ITD Cells.. <i>Blood</i> , 2006, 108, 4491-4491.	0.6	0
97	Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. <i>Leukemia</i> , 2005, 19, 1774-1782.	3.3	203
98	Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. <i>Nucleic Acids Research</i> , 2005, 33, 6895-6905.	6.5	37
99	Interferon α and T-cell responses in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 167-175.	0.6	31
100	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. <i>Blood</i> , 2004, 103, 3480-3489.	0.6	96
101	Monitoring Therapy with Gene Expression Profiling Reveals Physiological Differences in Drug Action. <i>Current Pharmaceutical Design</i> , 2004, 10, 1959-1968.	0.9	4
102	Interferon- γ , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. <i>Blood</i> , 2003, 101, 259-264.	0.6	131
103	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. <i>Journal of Cellular Biochemistry</i> , 2002, 86, 642-650.	1.2	35
104	CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up-regulated in distinct human leukaemias. <i>British Journal of Haematology</i> , 1999, 107, 494-504.	1.2	20
105	Determinants for transformation induced by the Axl receptor tyrosine kinase. <i>Oncogene</i> , 1998, 16, 3177-3187.	2.6	53
106	Recent Progress On the Role of Axl, A Receptor Tyrosine Kinase, in Malignant Transformation of Myeloid Leukemias. <i>Leukemia and Lymphoma</i> , 1997, 25, 91-96.	0.6	31